Pure Global AI
NCT06137469Not yet recruiting

Assessment of Gastric Emptying by SHR20004 in Healthy Subjects

A Single-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Multiple Subcutaneous Injections of SHR20004 in Healthy Subjects on Gastric Emptying
Jiangsu HengRui Medicine Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Type 2 Diabetes Mellitus
Drug/Device/Intervention
Acetaminophen/SHR20004
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu HengRui Medicine Co., Ltd.
Timeline & enrollment
Phase
Phase 1
Start date
Dec 15, 2023
End date
Feb 28, 2024
Enrollment
28 participants
Primary outcome

Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.：(AUC0-300min)

Summary

The purpose of this study is to investigate the impact of SHR20004 on the pharmacokinetic
 (PK) characteristics of acetaminophen in healthy subjects.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06137469
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06137469 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.